Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis

OBJECTIVES: To evaluate radiographic progression of structural joint damage over 2 years in patients with rheumatoid arthritis from baricitinib clinical trials who were disease-modifying antirheumatic drug (DMARD)–naïve or had an inadequate response to conventional synthetic DMARDs (csDMARD-IR). MET...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:RMD Open
Glavni autori: van der Heijde, Desirée, Schiff, Michael, Tanaka, Yoshiya, Xie, Li, Meszaros, Gabriella, Ishii, Taeko, Casillas, Marta, Ortmann, Robert A, Emery, Paul
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2019
Teme:
Rheumatoid Arthritis
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6525612/
https://ncbi.nlm.nih.gov/pubmed/31168413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2019-000898
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items